A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Fatty liver, which often accompanies obesity and type 2 diabetes, frequently leads to a much more debilitating hepatic disease including non-alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Current pharmacological therapies lack conclusive efficacy and thus treatment options are limited. Novel therapeutics that suppress either hepatic lipogenesis and/or hepatic inflammation may be useful. Here, we describe the development of the first selective synthetic LXR inverse agonist (SR9238) and demonstrate that this compound effectively suppresses hepatic lipogenesis, inflammation, and hepatic lipid accumulation in a mouse model of non-alcoholic hepatosteatosis. SR9238 displays high potency for both LXRα and LXRβ (40-200 nM IC50) and was designed to display liver specificity so as to avoid potential side effects due to suppression of LXR in the periphery. Unexpectedly, treatment of diet-induced obese mice with SR9238 suppressed plasma cholesterol levels. These data indicate that liver-selective LXR inverse agonists may hold utility in the treatment of liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978 · cited 1×
“activity is generally considered anti-inflammatory(23, 24), one might expect that a LXR”
BackgroundTranscriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779 · cited 1×
“expression of an array of lipogenic enzyme genes(6).”
BackgroundTosello-Trampont, A.-C., Landes, S. G., Nguyen, V., Novobrantseva, T. I., & Hahn, Y. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417014 · Cited by 415
Lima-Cabello, E., García-Mediavilla, M. V., Miquilena-Colina, M. E., Vargas-Castrillón, J., Lozano-Rodríguez, T., Fernández-Bermejo, M., Olcoz, J. L., González-Gallego, J., García-Monzón, C., & Sánchez-Campos, S. (2011) · Clinical Science · doi:10.1042/cs20100387 · Cited by 144 · cited 8×
“We hypothesized that either blocking activation of lipogenic enzyme expression or active suppression of these genes in the liver would be one method to treat NAFLD.”
BackgroundInfluential
Cited by
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279
The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease
Fessler, M. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.010 · Cited by 173
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
Griffett, K., Welch, R. D., Flaveny, C. A., Kolar, G. R., Neuschwander-Tetri, B. A., & Burris, T. P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.009 · Cited by 95
Self-citationRemembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Metadata
- Authors
- Griffett, K., Solt, L. A., El-Gendy, B. E.-D. M., Kamenecka, T. M., & Burris, T. P.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-12-27
- Volume
- 8
- Issue
- 3
- Pages
- 559-567
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2014864566
- Cited by
- 125
- References
- 9
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis. https://app.cochat.ai/papers/10.1021/cb300541g
- The paper
- Griffett, K., Solt, L. A., El-Gendy, B. E.-D. M., Kamenecka, T. M., & Burris, T. P. (2013). A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis. ACS Chemical Biology. https://doi.org/10.1021/cb300541g
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.